Form 8-K · Current report
MetLife 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0001099219
- Accession no.
- 0001099219-26-000058
Summary
MetLife reported third-quarter 2026 net income of $2.4 billion, or $3.67 per share, up 187% from the prior-year quarter, and adjusted earnings of $1.8 billion, up 12%. CEO Michel Khalaf said adjusted earnings per share excluding notable items of $2.85 were the highest in MetLife's history, driven by the company's New Frontier strategy and revenue growth in all six business segments.
Key points
- Net income rose 187% to $2.4 billion, or $3.67 per share, while adjusted earnings rose 12% to $1.8 billion.
- Adjusted earnings per share excluding total notable items rose 22% to $2.85.
- Premiums, fees and other revenues rose 12% to $14.1 billion, with adjusted PFOs excluding pension risk transfers up 8% to $13.5 billion.
- The annual actuarial assumption review reduced net income by $56 million and adjusted earnings by $46 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, MetLife, Inc. issued (i) a news release announcing its results for the quarter ended September 30, 2026 (the “Earnings Release”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, (ii) a Quarterly Financial Supplement for the quarter ended September 30, 2026 (the “Quarterly Financial Supplement”), a copy of which is attached hereto as Exhibit 99.2 and is incorporated herein by reference and (iii) a fact sheet setting forth its total assets under management as of September 30, 2026 (the “Total AUM Fact Sheet”), a copy of which is attached hereto as Exhibit 99.3 and is…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.